After three wins in cases over the risks of blockbuster blood thinner Xarelto, Bayer and Johnson & Johnson have encountered their first defeat. A jury in Philidelphia ordered the companies to pay $28 million to plaintiff Lynn Hartman. The companies plan
read moreNovo’s vaunted Victoza follow-up is here. The FDA on Tuesday approved Ozempic along with diet and exercise to improve glycaemic control in adults with Type 2 diabetes, setting it on a path expected to lead to blockbuster sales. More: Novo
read moreDepomed is selling off the franchise that was once the center of its growth hopes, and plenty of the company’s employees are leaving with it. Less than three years after shelling out $1.05 billion to acquire Nucynta ER and XR
read moreAs drug prices continue to weigh on public and private payers and as Congress hasn’t meaningfully addressed the issue, Arizona has unveiled a plan it thinks can help it fight spiraling costs. More: Arizona asks for permission to manage Medicaid
read moreThe deadline for completed multiple choice questionnaires (MCQ’s – Stage 1 of the competition) and essays (Stage 2, otherwise known as the ‘Clinical Challenge’) is 31 January and with the festive season approaching, it’s sure to come round much faster
read moreJohnson & Johnson’s blockbuster anti-TNF drug Remicade fell victim to biosimilar competition in Europe in 2015 and in the U.S. last year, but the impact of the inexpensive copycat drugs has been quite different in the two regions. More: As
read more© 1994 - 2026 B.M. Pharmaceuticals